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Background—Genetic variants on chromosome 4q25 are associated with atrial fibrillation (AF). We sought to determine
whether there is more than 1 susceptibility signal at this locus.
Methods and Results—Thirty-four haplotype-tagging single-nucleotide polymorphisms (SNPs) at the 4q25 locus were
genotyped in 790 case and 1177 control subjects from Massachusetts General Hospital and tested for association with
AF. We replicated SNPs associated with AF after adjustment for the most significantly associated SNP in 5066 case and
30 661 referent subjects from the German Competence Network for Atrial Fibrillation, Atherosclerosis Risk In
Communities Study, Cleveland Clinic Lone AF Study, Cardiovascular Health Study, and Rotterdam Study. All subjects
were of European ancestry. A multimarker risk score composed of SNPs that tagged distinct AF susceptibility signals
was constructed and tested for association with AF, and all results were subjected to meta-analysis. The previously
reported SNP, rs2200733, was most significantly associated with AF (minor allele odds ratio 1.80, 95% confidence
interval 1.50 to 2.15, P1.21020) in the discovery sample. Adjustment for rs2200733 genotype revealed 2 additional
susceptibility signals marked by rs17570669 and rs3853445. A graded risk of AF was observed with an increasing
number of AF risk alleles at SNPs that tagged these 3 susceptibility signals.
Conclusions—We identified 2 novel AF susceptibility signals on chromosome 4q25. Consideration of multiple susceptibility
signals at chromosome 4q25 identifies individuals with an increased risk of AF and may localize regulatory elements at the
locus with biological relevance in the pathogenesis of AF. (Circulation. 2010;122:976-984.)
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Atrial fibrillation (AF) is the most common arrhythmiaencountered in clinical practice and is associated with
substantial morbidity1 and societal healthcare costs.2 Al-
though many risk factors for AF have been identified, the
recognition of a common heritable component underlying
AF3,4 indicates that genetic variation may play a role in its
pathogenesis.
Clinical Perspective on p 984
We recently participated in a genome-wide association
study that identified a disease-susceptibility locus for AF on
chromosome 4q25 in individuals of European and Asian
descent.5 We replicated the association between the most
significantly associated single-nucleotide polymorphism
(SNP), rs2200733, and AF in a subsequent study of 3508
subjects with AF and 12 173 control subjects from 4 addi-
tional cohorts of European ancestry.6 A meta-analysis of the
results from both studies revealed an odds ratio (OR) of 1.9
for the rs2200733 risk allele (95% confidence interval [CI]
1.60 to 2.26, P3.31013).6 We and others have again
replicated the chromosome 4q25 AF susceptibility locus in
subsequent genome-wide association studies for AF.7–9
In the present study, we sought to identify whether there
are multiple AF susceptibility signals at the 4q25 locus in
individuals of European ancestry by performing fine mapping
of common SNPs in the region and replicating associations in
independent study samples. We further sought to determine
whether the consideration of multiple markers associated
with AF at this locus could further refine the association
signal.
Methods
Study Samples
Detailed descriptions of the study cohorts are provided in the
online-only Data Supplement. Individuals in the discovery stage of
the analysis were drawn from 2 different samples at the Massachu-
setts General Hospital (MGH) and pooled for analysis. These
samples included patients with lone AF referred to the Cardiac
Arrhythmia Service starting in June 2001 in whom AF was docu-
mented by ECG before 66 years of age and patients with AF by ECG
or history who were admitted to the MGH stroke service between
January 1998 and July 2006 with an acute ischemic or hemorrhagic
stroke. Referent subjects from MGH were from a large (18 000
patients) primary care practice serving the hospital catchment area.
Absence of AF was documented through interview and from review
of medical records, including all available ECGs.
Genetic variants associated with AF in the discovery sample after
adjustment for the top SNP (see Statistical Analysis) were genotyped
in an independent replication study sample composed of subjects
from the German Competence Network for Atrial Fibrillation
(AFNET), a national registry of AF patients.10 AF was confirmed by
ECG, and DNA samples were collected from patients with AF in
whom onset occurred before 60 years of age. Referent subjects were
derived from a community-based epidemiological survey study
conducted between 1999 and 2001 of persons living in or near the
city of Augsburg, Germany (Cooperative Health Research in the
Region of Augsburg [KORA] S4) and were excluded if they reported
a history of AF, had signs or symptoms of AF on physical
examination, or had an absence of sinus rhythm on a required ECG.11
We performed in silico replication of associations between AF and
SNPs that represented distinct susceptibility signals in MGH and
AFNET in 4 additional study samples with previously genotyped
subjects. The Atherosclerosis Risk In Communities (ARIC) study is
a prospective population-based study of cardiovascular disease in the
United States that consists of participants who were 45 to 64 years
old at enrollment. Subjects included in this analysis included those
recruited from 3 US communities (suburbs of Minneapolis, Minn;
Washington County, Maryland; and Forsyth County, North Caro-
lina) between 1987 and 1989.12 The Cleveland Clinic Lone AF Study
(CCAF) is composed of case subjects with AF in the absence of
significant structural heart disease. Referent subjects were popula-
tion controls from studies 64, 65, 66, and 67 in the Illumina iControl
database, a publicly accessible database of genotype and phenotype
data from control genome-wide association study populations. The
Cardiovascular Health Study (CHS) is a prospective population-
based study of cardiovascular disease in individuals 65 years or older
recruited from 4 field centers in the United States (Forsyth County,
North Carolina; Sacramento County, California; Washington
County, Maryland; and Pittsburgh, Pa).13 The Rotterdam Study (RS)
is a community-based longitudinal study of elderly individuals from
a suburb of Rotterdam, Netherlands, founded in 1990 with a focus on
identifying determinants of health and cardiovascular, neurogeriat-
ric, bone, and eye diseases.14
Prevalent AF was defined as events that occurred in individuals
before that individual’s DNA collection in cohort studies and on the
basis of AF ascertainment in case-control studies. Incident AF was
defined as events that occurred after DNA collection among partic-
ipants free of AF at DNA collection in cohort studies. Subjects were
restricted to those of self-reported European descent.
SNP Selection and Genotyping
A 200-kb region extending from the PITX2 gene to approximately 50
kb beyond the previously reported SNP rs2200733 was considered
for fine mapping of the chromosome 4q25 locus. All SNPs on
chromosome 4 between positions 111 780 000 and 111 985 000 with
a minor allele frequency of 5% or greater were identified from the
HapMap CEU data set release 22 (NCBI [National Center for
Biotechnology Information] build 36, dbSNP [database of SNPs]
build 126). We identified 35 haplotype-tagging SNPs (r20.8) in
this region using the Tagger program within Haploview version
4.0.15 Additionally, 6 SNPs that were moderately correlated with
rs2200733 (r2 between 0.2 and 0.8) were selected.
We extracted DNA from whole blood of each subject using
standard techniques. In the MGH and AFNET samples, genotyping
was performed with polymerase chain reaction, iPlex single-base
primer extension, and matrix-assisted laser desorption/ionization–
time-of-flight mass spectrometry in a 384-well format (Sequenom,
San Diego, Calif) according to the manufacturer’s instructions. Data
were analyzed with SpectroTYPER 3.4 software, and cluster plots
were inspected visually and curated manually to confirm genotyping
calls. The genotyping platforms for the remaining cohorts were
Affymetrix 6.0 (ARIC; Affymetrix, Santa Clara, Calif), Illumina
Hap550 version 3 and Illumina Hap610 version 1 (CCAF cases;
Illumina Inc, San Diego, Calif), Illumina Hap550 version 1 or 3
(CCAF referents), Illumina 370 CNV (CHS), and Illumina Infinium
HumanHap550 version 3 (RS). Only directly genotyped SNPs were
included in the analysis, with the exception of rs17570669 during the
replication stage in the CCAF sample. Imputation in CCAF was
performed with MACH version 1.0.16 (available at http://www.sph.
umich.edu/csg/abecasis/MaCH/index.html from the Center for Sta-
tistical Genetics of the University of Michigan) with the HapMap
CEU reference panel (NCBI build 36; Rsq 0.6144 for cases and
0.7302 for the iControl database controls). In CHS, genotypes for
rs17570669 were imputed with BIMBAM version 0.99,16 but these
were not included in the analyses owing to poor imputation quality
(ratio of observed to expected genotype variance of 0.11).
The institutional review board or medical ethics committee, as
appropriate for each participating institution, approved study proce-
dures. Written informed consent was obtained from all study subjects
or their proxies, including consent to use DNA for genetic analyses
of cardiovascular disease.
Statistical Analysis
We tested each SNP included in the discovery stage for deviation
from Hardy-Weinberg equilibrium using an exact test17 and excluded
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the SNP if P1104 in referent subjects. This corresponds to an
experiment-wide Hardy-Weinberg significance threshold of 0.005/
411104. We tested the remaining SNPs for association with AF
in the MGH sample using logistic regression assuming an additive
genetic model and subsequently adjusted for the genotype of the top
SNP to identify independent associations with AF. Significance
thresholds were adjusted for multiple testing by use of the Bonferroni
method, with an experiment-wide error rate of 0.05. Thirty-four
SNPs passed quality control measures, and therefore, the adjusted
significance threshold was P0.001 (0.05/34). We then tested SNPs
significantly associated with AF, after adjusting for the top SNP in
the MGH discovery sample, for association with AF in the AFNET
sample.18
To identify SNPs that represented distinct AF susceptibility
signals, we calculated pairwise linkage disequilibrium measures r2
and D in the MGH and AFNET samples and constructed linkage
disequilibrium blocks using Haploview15 with previously described
definitions.19 We inferred haplotypes composed of SNPs located on
the same block from unphased data using an expectation-
maximization algorithm and tested haplotypes for association with
AF using a weighted logistic regression model with adjustment for
genotypes of the remaining SNPs that marked separate AF suscep-
tibility signals.20 Haplotypes were weighted according to the poste-
rior probability of possible haplotype pairs for each individual
subject.20
The SNPs associated with AF in both the MGH and AFNET
samples that were markers for independent signals were then
assessed for association with AF in the additional replication cohorts
by use of logistic regression in samples with prevalent AF (CCAF,
CHS, and RS) and Cox proportional hazards regression in samples
with incident AF (ARIC, CHS, and RS). Individuals were censored
at death, loss to follow-up, or date of last contact. Person-time for the
incident analyses began at the time of DNA collection. Associations
were adjusted for significant principal components of race for those
studies in which population structure was associated with AF. Both
prevalent and incident associations were subjected to meta-analysis
by an inverse-variance weighted fixed-effects method.21
Because indirectly measured haplotype phasing is accompanied by
uncertainty, we used the combination of genotypes at SNPs that
marked each distinct AF susceptibility signal to define a multimarker
variable for each individual. We assessed the association between
each multimarker combination of genotypes and AF relative to the
most common combination of genotypes for these SNPs, allowing
for separate effects for each genotype combination. The effects were
meta-analyzed as described above. In samples with incident AF, the
time-dependent area under the receiver operating characteristic curve
was estimated for models with and without the multimarker variables
included.22
For the discovery stage of the analysis in the MGH sample of 790
cases and 1177 referent subjects, we estimated that we would have
41% power to detect ORs of 1.5 for risk alleles with frequencies of
5% and 80% power to detect ORs of 1.5 for risk alleles with
frequencies of at least 10%, assuming a 2-sided -level of 0.001 and
population disease prevalence of 1%.23
Statistical analyses were performed with PLINK version 1.06,24 SAS
version 9.1.3 (SAS Institute, Cary, NC), and R version 2.11 (The R
Project for Statistical Computing; available at http://www.R-project.
org). Regional association plots were prepared with SNAP.18
Results
A total of 790 subjects with AF and 1177 referent subjects
from MGH were included in the discovery stage of the
analysis. Among the 790 case subjects, 488 were from the
MGH lone-AF cohort, and 302 were from the MGH stroke
cohort (Table 1). The overall call rate for the 34 SNPs tested
for association with AF was 98.9%.
There was a strong association between AF and SNPs on
chromosome 4q25 (Table 2; Figure 1A; online-only Data
Supplement Table I). Among the 34 SNPs examined, 15
exceeded the significance threshold of P0.001 after adjust-
ment for age, sex, and hypertension. The most significant
association with AF observed at this locus was with the
previously reported SNP, rs2200733, with an OR for the
minor T allele of 1.80 (95% CI 1.50 to 2.15, P1.21010).
A second SNP previously reported to confer an independent
risk of AF, rs10033464,5 was not significantly associated
with AF in the present sample (OR for minor T allele 1.07,
95% CI 0.84 to 1.35, P0.59).
We then performed analyses with adjustment for
rs2200733 genotype. The 4 SNPs most significantly associ-
ated with AF were all located within 30 kb of one another and
telomeric to rs2200733 (Figure 1; online-only Data Supple-
ment Table II). Associations between these 4 SNPs and AF
after adjustment for age, sex, hypertension, and rs2200733
genotype (rs17570669: OR for minor T allele 0.60, 95% CI
0.46 to 0.78, P2.0104; rs4124163: OR for minor G allele
0.56, 95% CI 0.39 to 0.81, P2.3103; rs6838973: OR for
minor T allele 0.77, 95% CI 0.67 to 0.89, P3.4104; and
rs3853445: OR for minor C allele 0.75, 95% CI 0.64 to 0.89,
P6.9104) were similar to unadjusted associations
(online-only Data Supplement Table II). The minor alleles for
each of these 4 SNPs were associated with a lower risk of AF.
Although rs3853445 and rs6838973 were both associated
with AF before adjustment for rs2200733, the association
between rs17570669 and AF was not evident until after
adjustment for rs2200733. There was a suggestion of a
separate signal associated with AF centromeric to rs2200733;
however, no SNPs in this region were significantly associated
with AF after adjustment for multiple comparisons (Figure 1;
online-only Data Supplement Table II).
Table 1. Characteristics of Study Subjects
Replication Stage
Prevalent Analysis Incident AnalysisDiscovery Stage
Prevalent Analysis
MGH Cohort AFNET Cohort CCAF Cohort CHS Cohort RS Cohort ARIC Cohort CHS Cohort RS Cohort
AF No AF AF No AF AF No AF AF No AF AF No AF AF No AF AF No AF AF No AF
No. of subjects 790 1177 2145 4073 496 2971 66 3205 309 5665 743 7184 765 2440 542 5123
Age, y 6315 6713 4914 6112 5811 2822 766 725 768 699 575 546 736 725 728 699
Female, % 31 47 27 51 24 62 52 39 53 60 40 54 45 37 54 60
Hypertension, % 49 57 56 18 54 Unknown 52 52 42 33 44 25 59 50 45 32
Data presented as meanSD or %.
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Characteristics of the 2145 case and 4073 referent subjects
in the AFNET sample are displayed in Table 1. In addition to
rs2200733, 3 of the 4 SNPs associated with AF in the MGH
discovery cohort analysis passed quality control measures
with an overall call rate of 94.4% and were tested for
association with AF. As in the MGH sample, with adjustment
for age, sex, and hypertension, rs2200733 (P3.81052),
rs3853445 (P2.14107), and rs6838973 (P1.45108)
were associated with AF, but rs17570669 (P0.28) was not.
After additional adjustment for rs2200733 genotype, signifi-
cant associations with AF were observed for the remaining 3
SNPs (rs17570669: minor T allele OR 0.64, 95% CI 0.54 to
0.77, P5.3107; rs3853445: minor C allele OR 0.82, 95%
CI 0.74 to 0.91, P1.1104; and rs6838973: minor T allele
OR 0.81, 95% CI 0.74 to 0.89, P5.4106).
Pairwise linkage disequilibrium measures revealed that
SNPs rs3853445 and rs6838973 were moderately correlated
(r2 0.43 and 0.41 in MGH and AFNET, respectively) and
located on the same haplotype block in both samples, which
suggests that associations between each of these 2 SNPs and
AF represented the same signal (online-only Data Supple-
ment Table III). Because rs6838973 was not genotyped
directly in the remaining replication samples, rs3853445 was
used for subsequent analyses as a marker for this suscepti-
bility signal. In contrast, there was a very low level of
correlation between the remaining SNPs (r20.11 for all
Table 2. Fine Mapping of the Locus for AF on Chromosome 4q25 in the Discovery Sample From MGH
Minor Allele
Frequency, %
SNP Position Minor/Major Allele AF No AF Adjusted OR (95% CI)* P
rs17554590 111 782 351 G/C 1.7 2.0 0.97 (0.59–1.61) 0.91
rs2595098 111 782 931 A/T 4.8 7.1 0.63 (0.46–0.84) 2.9103
rs1448818 111 789 672 C/A 30.1 25.7 1.24 (1.07–1.44) 4.7103
rs12498374 111 803 868 T/C 25.0 19.9 1.32 (1.12–1.55) 7.0104
rs1448822 111 820 547 A/G 36.0 30.6 1.26 (1.09–1.45) 1.5103
rs13120244 111 823 793 A/G 10.0 12.4 0.83 (0.67–1.03) 0.09
rs1900827 111 843 188 T/C 40.0 31.2 1.41 (1.23–1.62) 7.8107
rs4371683 111 846 216 A/C 40.1 31.6 1.40 (1.22–1.61) 1.5106
rs17042026 111 851 823 A/G 26.1 16.8 1.64 (1.39–1.92) 2.8109
rs12646859 111 854 082 G/T 14.1 14.7 0.99 (0.82–1.19) 0.89
rs10222783 111 854 275 T/C 3.6 2.3 1.56 (1.02–2.37) 0.04
rs2595085 111 856 222 G/C 40.2 31.8 1.40 (1.22–1.60) 2.0106
rs1448817 111 860 502 G/A 38.0 27.6 1.51 (1.31–1.74) 8.4109
rs11098090 111 875 857 C/T 14.8 14.2 1.04 (0.86–1.26) 0.68
rs4307025 111 876 952 A/T 37.8 27.4 1.50 (1.31–1.73) 1.2108
rs2634071 111 888 669 T/C 28.9 19.2 1.60 (1.37–1.87) 2.0109
rs2723333 111 918 540 A/G 8.9 12.0 0.74 (0.59–0.92) 6.7103
rs1906615 111 921 247 T/G 30.1 20.6 1.54 (1.32–1.80) 2.6108
rs2200733 111 929 618 T/C 21.5 11.7 1.80 (1.50–2.15) 1.21010
rs13143308 111 933 868 T/G 31.7 21.1 1.60 (1.38–1.86) 9.51010
rs13105878 111 937 596 A/C 7.8 10.8 0.73 (0.58–0.93) 9.7103
rs11931959 111 939 134 G/A 38.2 28.5 1.47 (1.28–1.69) 7.8108
rs10033464 111 940 210 T/G 9.2 8.5 1.07 (0.84–1.35) 0.59
rs3855819 111 946 612 G/C 14.3 13.2 1.09 (0.90–1.32) 0.38
rs6533531 111 951 414 G/T 47.3 37.0 1.43 (1.24–1.64) 5.9107
rs3853444 111 953 585 C/T 29.7 30.8 0.95 (0.82–1.10) 0.49
rs17570669 111 956 331 T/A 7.2 8.5 0.87 (0.67–1.12) 0.28
rs13130446 111 958 605 T/C 49.8 49.8 1.02 (0.89–1.16) 0.80
rs10516564 111 958 741 G/A 29.1 30.0 0.93 (0.80–1.08) 0.33
rs3866834 111 963 462 A/G 33.9 34.0 1.02 (0.89–1.18) 0.79
rs4124163 111 965 048 G/A 3.0 5.0 0.61 (0.42–0.87) 6.1103
rs3853445 111 980 936 C/T 20.3 26.2 0.71 (0.61–0.84) 4.1105
rs6838901 111 984 764 C/G 13.6 14.6 0.93 (0.77–1.13) 0.47
rs6838973 111 984 944 T/C 34.6 41.5 0.75 (0.66–0.86) 4.8105
Genomic position from NCBI build 36. OR is the OR that corresponds to the minor allele.
*Adjusted for age, sex, and hypertension.
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pairwise comparisons), as expected on the basis of the
haplotype-tagging SNP selection method.
We therefore tested the 3 independent susceptibility signals
for association with AF by modeling the 2 independent SNPs
along with inferred rs3853445 and rs6838973 haplotypes
(Table 3). The haplotype consisting of the minor alleles for
both rs3853445 and rs6838973 (CT) occurred with a fre-
quency of 23% in the MGH sample and 26% in the AFNET
sample and conferred reduced odds of AF relative to the
major allele haplotype (TC) after adjustment for rs2200733
and rs17570669 genotype (combined OR 0.78, 95% CI 0.71
to 0.87, P1.75106). The remaining 2 susceptibility
signals marked by rs2200733 and rs17570669 remained
significantly associated with AF in the combined analysis,
although the association for rs17570669 was attenuated in the
MGH sample.
Associations between SNPs that represented distinct AF
susceptibility signals in the MGH and AFNET samples were
then tested for replication in the ARIC, CCAF, CHS, and RS
study samples. Characteristics of these samples are displayed
in Table 1. In general, the associations were replicated in the
prevalent AF samples but not in the incident AF samples,
although effect estimates tended to be in the same direction as
those observed in the discovery sample (Figure 2).
We then calculated the relative risk of AF for each
multimarker combination of genotypes for SNPs that tagged
each of the 3 AF susceptibility signals relative to the most
common combination of genotypes in each of the study
samples (Figure 3). The multimarker analysis indicated a
graded risk of AF that generally corresponded to the number
of AF risk alleles, although the risks varied within strata
defined by numbers of risk alleles, and CIs overlapped for
Figure 1. Regional plot of SNPs associated with prevalent AF in the MGH discovery sample. A, Associations between SNPs included
in the analysis and AF in the MGH sample, adjusted for age, sex, and hypertension. B, Associations after additional adjustment for
rs2200733 genotype, with the rs2200733 position corresponding to the unadjusted association significance level. SNPs are plotted
according to their genomic position (NCBI build 36) and log10 probability value for the association. The intensity of shading for each
SNP corresponds to the strength of linkage disequilibrium (r2) relative to rs2200733. Estimated recombination rates are shown by the
blue line. PITX2 is indicated by the dark green arrow. Linkage disequilibrium and recombination rates are based on CEU HapMap
release 22. SNPs that were associated with AF after adjustment for rs2200733 genotype and meta-analysis of results from both the
MGH and AFNET samples are labeled. Figures were prepared with SNAP.18
Table 3. Associations Between AF and rs2200733, rs17570669, and Common rs3853445Prs6838973 Haplotypes in the MGH and
AFNET Samples
Variant
Haplotype
Frequency
MGH
Haplotype
Frequency
AFNET Combined†
OR (95% CI) P OR (95% CI) P OR (95% CI) P
rs2200733 . . . 1.87 (1.54–2.27) 2.41010 . . . 2.64 (2.32–3.00) 3.41049 2.37 (2.13–2.64) 3.11056
rs17570669 . . . 0.74 (0.55–1.01) 0.06 . . . 0.70 (0.58–0.85) 2.8104 0.71 (0.61–0.84) 4.3105
rs3853445Prs6838973
Haplotype
TC 0.60 Reference . . . 0.56 Reference . . . Reference . . .
TT 0.16 0.92 (0.75–1.13) 0.45 0.17 0.99 (0.86–1.13) 0.89 0.97 (0.87–1.09) 0.59
CC 0.01 1.24 (0.58–2.66) 0.57 0.01 1.87 (1.21–2.91) 5.0103 1.69 (1.16–2.47) 7.0103
CT* 0.23 0.75 (0.63–0.90) 1.6103 0.26 0.80 (0.71–0.90) 2.7104 0.78 (0.71–0.87) 1.75106
Adjusted for age, sex, and hypertension. OR is the OR that corresponds to the minor allele or specified haplotype.
*Composed of the minor alleles for each respective SNP.
†Meta-analysis performed using a fixed-effects method.
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many of the multimarker groups owing to small sample
sizes. The relative risks of AF for the 3 most frequent
rs2200733/rs17570669/rs3853445 genotype combinations
(relative to the most common genotype combination CC/
AA/TT, composed of 4 AF risk alleles; 38% of subjects)
were 0.90 (95% CI 0.82 to 0.99, CC/AA/CT [3 risk alleles,
26% of subjects]), 1.74 (95% CI 1.48 to 2.03, CT/AA/CT
[4 risk alleles, 5% of subjects]), and 2.26 (95% CI 2.02 to
2.53, CT/AA/TT [5 risk alleles, 10% of subjects]). The
greatest relative risk was observed with the combination
comprised of both AF risk alleles at each of the 3 SNPs,
TT/AA/TT, which occurred in approximately 1% of sub-
jects (relative risk 6.02, 95% CI 4.56 to 7.96). The
associations, stratified by prevalent or incident status, are
displayed in online-only Data Supplement Figure II.
In samples with incident AF, the time-dependent area
under the curve for a model with age, sex, and hypertension
was 0.70 (95% CI 0.69 to 0.72) and 0.68 (95% CI 0.66 to
0.70) over the follow-up periods in ARIC and RS, respec-
tively. The area under the curve increased to 0.72 (95% CI
0.70 to 0.73) and 0.70 (95% CI 0.68 to 0.72), respectively,
after the addition of the multimarker allele combinations.
Discussion
In the present study sample of subjects from MGH, the
previously reported SNP, rs2200733, remained the variant
most significantly associated with AF even after consider-
ation of other SNPs at the chromosome 4q25 locus. In
addition to this signal, we identified 2 novel AF susceptibility
signals after adjustment for rs2200733 genotype in a meta-
analysis of 5856 subjects with AF and 31 838 without AF, all
of whom were of European ancestry. A multimarker risk
score composed of SNPs that tagged each of these 3 AF
susceptibility signals on chromosome 4q25 identified indi-
Figure 2. SNPs associated with AF after
adjustment for rs2200733 genotype. SNPs
associated with AF after adjustment for
rs2200733 genotype in the MGH discovery
sample were tested for association in the repli-
cation samples. The meta-analyzed effects are
plotted according to prevalent (OR), incident
(hazard ratio), or pooled (relative risk [RR]) anal-
ysis status. Associations were adjusted for age,
sex, and hypertension (MGH, AFNET, ARIC,
CHS, and RS) or sex only (CCAF). Samples
with prevalent AF included MGH, AFNET, CHS,
CCAF, and RS. Samples with incident AF
included ARIC, CHS, and RS. NA indicates not
available.
Figure 3. Multimarker risk score for AF based on combined rs2200733, rs17570669, and rs3853445 genotypes. The meta-analyzed rel-
ative risk (RR) of AF for each multimarker combination of rs2200733, rs17570669, and rs3853445 genotypes relative to the most com-
mon multimarker combination is shown. Only multimarker combinations with an average sample frequency of 0.2% are displayed,
although the effects were adjusted for all potential combinations, as well as age, sex, and hypertension, or sex only (CCAF). Individuals
with incomplete genotypes were not included. Risk alleles for AF were the minor T allele for rs2200733, the major A allele for
rs17570669, and the major T allele for rs3853445.
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viduals at varying risk of developing AF, which approxi-
mately corresponded to the number of AF risk alleles present.
The present results reinforce the association between chro-
mosome 4q25 and AF and extend the knowledge base by
defining the genetic architecture of this locus and its relation
to AF.5–8 Specifically, SNPs rs17570669, rs3853445, and
rs6838973 were confined to a 30-kb region from the 200-kb
region assayed and located within 50 kb telomeric of
rs2200733. The locus studied in the present analysis is
marked by regions that appear to be phylogenetically con-
served (online-only Data Supplement Figure III).25 Indeed,
there is emerging evidence that highly conserved noncoding
regions may act as regulatory elements and underlie pheno-
typic diversity.26,27 However, the mechanism by which ge-
netic variation at the chromosome 4q25 locus leads to AF
remains unknown.
The lack of significant association in the incident AF
samples between AF and SNPs rs17570669 and rs3853445,
after adjustment for rs2200733 genotype, may reflect reduced
power in the incident stratum, an absence of true association
when modeled in this fashion, interactions between variants
and unmeasured clinical factors that differ between prevalent
and incident AF, or other phenotypic heterogeneity between
prevalent and incident AF. A multimarker risk score com-
posed of AF risk alleles at SNPs that tagged these 3
susceptibility signals identified individuals predisposed to the
development of AF, which raises the possibility that consid-
eration of multiple genetic variants at the chromosome 4q25
locus may help improve risk stratification of individuals at
risk for AF.28 Whether the consideration of the 3 signals
identified in the present analysis will contribute to AF
prediction in the context of additional variants associated
with AF7–9,29,30 is presently unclear but merits examination in
larger prospective data sets.
Study Limitations
The present analysis was restricted to individuals of European
descent, and therefore, the findings may not be generalizable
to individuals of other races and ethnicities. Although we
could not assess for population stratification in the MGH and
AFNET samples, the relative homogeneity of the present
study cohorts limits the likelihood of such confounding.
Furthermore, we adjusted analyses for population structure in
replication cohorts when there was evidence of association with
AF. We did not restrict the age of subjects included in the
analysis. Although the chromosome 4q25 region has been
associated with AF in subjects with a diverse spectrum of
presumed causes,7,9,31,32 including those with lone AF9 and
typical forms of AF,7 sources of heterogeneity in the discovery
cohort that were not accounted for may have affected the SNPs
selected for replication. The haplotype and multimarker risk
score analyses represent multiple testing, and several sub-
groups were of small sample size, as reflected by the wide CIs
that accompanied some effect estimates; positive associations
may represent “winner’s curse.”33 Although we did not adjust
for multiple testing at this stage, the observed associations are
supported by the fact that SNPs tested in these analyses were
selected after conservative Bonferroni-adjusted association
thresholds in the discovery analysis. Moreover, patterns of
association for these subgroups were consistent across inde-
pendent study samples. We are unable to rule out longer-
distance associations at the locus beyond the boundaries of
the present SNP selection region. Lastly, although we cannot
exclude the possibility that all of the identified SNPs merely
tag a single, common element associated with AF, the low
correlation between the SNPs identified in the present anal-
ysis and the haplotype association analysis suggest that these
SNPs represent 3 independent signals at the chromosome
4q25 locus that affect AF risk.
Conclusions
We confirmed the strong association between AF and
rs2200733 at the chromosome 4q25 locus and identified 2
novel disease susceptibility signals that are associated with
AF. Simultaneous consideration of these signals identifies
individuals with an increased risk for AF.
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CLINICAL PERSPECTIVE
Atrial fibrillation (AF) is a heritable disorder with evidence of genetic susceptibility. Common single-nucleotide
polymorphisms (SNPs) in a noncoding region on chromosome 4q25 have been associated with AF. We sought to determine
whether more than 1 AF susceptibility signal exists at this locus. We genotyped SNPs at the chromosome 4q25 locus in
790 case subjects and 1177 control subjects. After adjustment for the genotype of the most significantly associated SNP,
the SNPs that remained significantly associated with AF were replicated in an additional 5066 subjects with AF and 30 661
without AF. We identified 3 distinct AF susceptibility signals, 2 of which have not been described previously. A
multimarker risk score composed of SNPs tagging each of these 3 AF susceptibility signals identified individuals at varying
risk of developing AF. Among the 1% of subjects homozygous for AF risk alleles at SNPs tagging each susceptibility
signal, the risk of AF was markedly increased relative to those with the most common genotypes at these SNPs (relative
risk 6.02, 95% confidence interval 4.56 to 7.96, P1.21036). Consideration of multiple susceptibility signals at the
chromosome 4q25 locus identifies individuals with a markedly increased risk of AF and may facilitate the localization of
regulatory elements at this locus with particular biological relevance in the pathogenesis of AF.
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SUPPLEMENTAL METHODS 
The Massachusetts General Hospital (MGH) lone AF sample consisted of patients 
with AF referred to the Cardiac Arrhythmia Service starting in June 2001 in whom AF was 
documented by electrocardiogram before 66 years of age.  Exclusion criteria included any 
history of structural heart disease, rheumatic heart disease, hyperthyroidism, myocardial 
infarction, or heart failure prior to the onset of AF.  Each patient underwent a standardized 
interview and physical examination to identify relevant clinical characteristics, a 12-lead 
electrocardiogram, and blood draw for collection of DNA.  The MGH Stroke sample included 
patients with AF by electrocardiogram or history who were admitted to the MGH Stroke service 
between January 1998 and July 2006 with an acute ischemic or hemorrhagic stroke confirmed 
by brain computed tomography or magnetic resonance imaging.  Patients with primary 
subarachnoid hemorrhage or intracerebral hemorrhage secondary to head trauma, tumor, 
vascular malformation, or vasculitis were excluded.  Referent subjects from MGH were recruited 
from a large, primary care practice of greater than 18,000 patients serving the hospital 
catchment area.  All subjects, or a family informant, were interviewed prospectively regarding 
medical, medication, social and family history.  Absence of AF was prospectively documented 
through interview and from review of medical records including all available electrocardiograms.   
The German Competence Network for Atrial Fibrillation (AFNET) is a national registry of 
AF patients.1  AF was confirmed by electrocardiogram, and DNA samples were collected from 
patients with AF in whom onset occurred before 60 years of age.  Patients with New York Heart 
Association class III or IV heart failure, moderate to severe valvular disease, or hyperthyroidism 
were excluded from the study.  Referent subjects were derived from a community-based 
epidemiologic survey study conducted between 1999 and 2001 of persons living in or near the 
city of Augsburg, Southern Germany (KORA S4).2  Study participants were equally distributed 
male and female residents of German nationality between 25 to 74 years of age.  Referent 
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subjects were excluded if they reported a history of AF, had signs or symptoms of AF on 
physical examination, or absence of sinus rhythm on a required electrocardiogram. 
The Cleveland Clinic Lone AF Study (CCAF) is comprised of subjects with lone AF, 
defined as those with AF in the absence of significant structural heart disease with recurring or 
persistent lone AF, absence of clinical evidence of coronary artery stenosis or documented 
stenosis ≤50%, and a left ventricular ejection fraction (LVEF) ≥ 50%.  Subjects with heart failure, 
significant valvular disease (>2+ valvular regurgitation, any valvular stenosis), prior myocardial 
infarction, prior percutaneous coronary intervention, prior coronary artery bypass graft, 
congenital heart disease, hypertrophic cardiomyopathy, aortic dissection or repair, were 
excluded.  All subjects from Studies 64, 65, 66 and 67 in the Illumina iControl database were 
used as the referent controls.  
The Atherosclerosis Risk in Communities (ARIC) study is a prospective population-
based study of subjects in the United States (73% of European descent) aged 45 to 64 at 
enrollment, recruited from 4 US communities (suburbs of Minneapolis, Minnesota; Washington 
County, Maryland; Jackson, Mississippi; and Forsyth County, North Carolina) between 1987-
1989 to investigate the epidemiology of cardiovascular disease.3  Participants underwent 
electrocardiograms at baseline and at each follow-up exam (3 exams; 1 exam every 3 years).  
Incident AF was classified as the first occurrence of AF through 2005 as identified from 
electrocardiograms at study visits, hospital discharge codes or death certificates (ICD-9 code 
427.31 or 427.32, or ICD-10 code I48). The sensitivity and positive predictive value of hospital 
discharge codes for the diagnosis of incident AF, as determined after review of hospital 
discharge summaries in a sample of ARIC participants, was close to 90%.4  Only subjects of 
self-reported European ancestry were included in this analysis; thus, subjects recruited from 
Jackson, Mississippi, and a small group of subjects from Forsyth County, North Carolina, were 
not included.   
Page 5 of 12 
The Rotterdam Study (RS) is a community-based study of elderly individuals from a 
suburb of Rotterdam with a focus on identifying determinants of health and cardiovascular, 
neurogeriatric, bone, and eye diseases. Participants age ≥ 55 years were examined up to 4 
times every 3 years.5 AF was diagnosed based on study visit electrocardiograms, review of 
hospital discharge information, and general practitioner diagnoses. AF was verified by 2 
physicians and disagreements settled by review of a cardiologist.6 
The Cardiovascular Health Study (CHS) is a prospective population-based study of 
cardiovascular disease in individuals 65 years or older recruited from 4 Field Centers (Forsyth 
County, NC; Sacramento County, CA; Washington County, MD; Pittsburgh, PA).7  Prevalent AF 
was that which was present on the baseline electrocardiogram.  Incident AF was classified at 
the occasion of first AF identified during an annual CHS electrocardiogram or by ICD-9 code on 
a hospital discharge.  
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SUPPLEMENTAL TABLES 
Supplemental Table 1. Fine mapping of the locus for atrial fibrillation on chromosome 4q25 in 
the MGH study sample stratified by case subject cohort. 
 
Lone 
(N=488 cases, 727 referent) 
Stroke 
(N=302 cases, 450 referent) SNP 
Odds ratio 
(95% CI) P Value 
Odds ratio 
(95% CI) P Value 
rs17554590 0.66 (0.27-1.58) 0.35 1.07 (0.50-2.31) 0.86 
rs2595098 0.70 (0.44-1.11) 0.13 0.64 (0.38-1.07) 0.09 
rs1448818 1.20 (0.96-1.50) 0.12 1.23 (0.95-1.60) 0.12 
rs12498374 1.26 (0.98-1.61) 0.07 1.37 (1.04-1.81) 0.03 
rs1448822 1.23 (0.99-1.52) 0.06 1.18 (0.92-1.53) 0.19 
rs13120244 0.74 (0.52-1.05) 0.09 1.10 (0.77-1.56) 0.61 
rs1900827 1.79 (1.45-2.22) 1.1x10-7 0.97 (0.76-1.23) 0.79 
rs4371683 1.79 (1.44-2.22) 1.5x10-7 0.96 (0.76-1.23) 0.76 
rs17042026 1.99 (1.54-2.55) 9.6x10-8 1.14 (0.85-1.51) 0.39 
rs12646859 1.23 (0.90-1.67) 0.19 0.80 (0.58-1.09) 0.16 
rs10222783 2.67 (1.36-5.22) 4.2x10-3 0.98 (0.47-2.06) 0.96 
rs2595085 1.79 (1.44-2.22) 1.3x10-7 0.96 (0.75-1.22) 0.71 
rs1448817 1.94 (1.56-2.43) 4.3x10-9 1.02 (0.80-1.30) 0.87 
rs11098090 1.30 (0.97-1.76) 0.08 0.77 (0.56-1.07) 0.12 
rs4307025 1.95 (1.56-2.44) 3.5x10-9 1.01 (0.79-1.29) 0.92 
rs2634071 2.13 (1.68-2.72) 8.5x10-10 0.98 (0.74-1.29) 0.89 
rs2723333 0.81 (0.57-1.15) 0.24 0.80 (0.56-1.16) 0.24 
rs1906615 1.97 (1.56-2.50) 2.1x10-8 0.96 (0.73-1.25) 0.75 
rs2200733 2.26 (1.72-2.97) 5.5x10-9 1.17 (0.85-1.63) 0.34 
rs13143308 2.11 (1.67-2.67) 4.9x10-10 0.97 (0.74-1.27) 0.83 
rs13105878 0.49 (0.33-0.73) 4.3x10-4 1.09 (0.75-1.59) 0.65 
rs11931959 1.60 (1.29-1.99) 1.9x10-5 1.14 (0.89-1.45) 0.31 
rs10033464 1.46 (1.02-2.08) 0.04 0.60 (0.39-0.92) 0.02 
rs3855819 1.03 (0.77-1.38) 0.85 1.01 (0.73-1.41) 0.95 
rs6533531 1.87 (1.49-2.34) 5.2x10-8 0.93 (0.74-1.18) 0.57 
rs3853444 0.97 (0.78-1.22) 0.7989 1.00 (0.77-1.29) 0.99 
rs17570669 0.67 (0.44-1.02) 0.06 1.11 (0.73-1.69) 0.61 
rs13130446 1.08 (0.88-1.32) 0.48 1.02 (0.81-1.29) 0.86 
rs10516564 0.87 (0.70-1.09) 0.22 0.98 (0.76-1.26) 0.88 
rs3866834 1.06 (0.84-1.32) 0.63 0.99 (0.78-1.25) 0.92 
rs4124163 0.43 (0.24-0.77) 4.7x10-3 0.95 (0.54-1.69) 0.87 
rs3853445 0.75 (0.59-0.97) 0.03 0.72 (0.54-0.94) 0.02 
rs6838901 0.85 (0.63-1.14) 0.28 0.84 (0.60-1.18) 0.31 
rs6838973 0.73 (0.59-0.90) 3.9x10-3 0.74 (0.59-0.94) 0.01 
 
Adjusted for age, sex, hypertension.  
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Supplemental Table 2. Fine mapping of the locus for atrial fibrillation on chromosome 4q25 in 
the MGH discovery sample after adjusting for rs2200733 genotype. 
 
SNP Adjusted for rs2200733 Adjusted for rs2200733, age, and sex  
Adjusted for rs2200733, 
age, sex, and 
hypertension 
 
Odds ratio 
(95% CI) P Value 
Odds ratio 
(95% CI) P Value 
Odds ratio 
(95% CI) P Value 
rs17554590 1.00 (0.61-1.62) 0.98 1.10 (0.66-1.83) 0.71 1.10 (0.66-1.83) 0.72 
rs2595098 0.76 (0.57-1.01) 0.06 0.72 (0.53-0.98) 0.03 0.71 (0.52-0.96) 0.03 
rs1448818 1.16 (1.01-1.35) 0.04 1.16 (0.99-1.35) 0.07 1.16 (1.00-1.35) 0.06 
rs12498374 1.24 (1.05-1.45) 9.1x10-3 1.20 (1.02-1.42) 0.03 1.21 (1.03-1.43) 0.02 
rs1448822 1.21 (1.05-1.39) 7.8x10-3 1.19 (1.03-1.37) 0.02 1.20 (1.03-1.38) 0.02 
rs13120244 0.82 (0.67-1.02) 0.07 0.87 (0.70-1.08) 0.20 0.87 (0.69-1.08) 0.20 
rs1900827 1.14 (0.97-1.34) 0.10 1.15 (0.97-1.35) 0.11 1.15 (0.98-1.36) 0.09 
rs4371683 1.13 (0.97-1.33) 0.12 1.14 (0.96-1.34) 0.13 1.15 (0.97-1.35) 0.11 
rs17042026 1.24 (1.00-1.55) 0.05 1.22 (0.97-1.54) 0.09 1.22 (0.97-1.53) 0.09 
rs12646859 1.04 (0.86-1.25) 0.71 1.05 (0.87-1.28) 0.60 1.07 (0.88-1.29) 0.52 
rs10222783 1.92 (1.27-2.89) 1.9x10-3 1.81 (1.18-2.79) 6.5x10-3 1.82 (1.18-2.80) 6.4x10-3 
rs2595085 1.12 (0.96-1.31) 0.16 1.12 (0.95-1.33) 0.17 1.13 (0.96-1.33) 0.14 
rs1448817 1.26 (1.06-1.50) 8.4x10-3 1.24 (1.03-1.48) 0.02 1.24 (1.04-1.49) 0.02 
rs11098090 1.22 (1.01-1.47) 0.04 1.19 (0.98-1.45) 0.08 1.20 (0.99-1.46) 0.07 
rs4307025 1.27 (1.07-1.51) 7.4x10-3 1.23 (1.03-1.48) 0.03 1.24 (1.03-1.49) 0.02 
rs2634071 1.20 (0.94-1.53) 0.14 1.22 (0.94-1.58) 0.13 1.23 (0.95-1.59) 0.12 
rs2723333 0.81 (0.65-1.01) 0.06 0.83 (0.66-1.04) 0.10 0.82 (0.66-1.03) 0.08 
rs1906615 1.19 (0.94-1.50) 0.14 1.17 (0.91-1.49) 0.22 1.17 (0.92-1.50) 0.21 
rs13143308 1.31 (1.05-1.63) 0.02 1.26 (0.99-1.59) 0.06 1.26 (1.00-1.60) 0.05 
rs13105878 0.78 (0.61-0.98) 0.03 0.81 (0.63-1.03) 0.09 0.81 (0.64-1.03) 0.09 
rs11931959 1.20 (1.01-1.44) 0.04 1.18 (0.98-1.42) 0.08 1.18 (0.98-1.42) 0.09 
rs10033464 1.24 (0.99-1.56) 0.06 1.20 (0.95-1.53) 0.13 1.21 (0.95-1.54) 0.12 
rs3855819 1.26 (1.04-1.52) 0.02 1.24 (1.02-1.51) 0.03 1.24 (1.02-1.51) 0.03 
rs6533531 1.22 (1.04-1.43) 0.02 1.18 (0.99-1.39) 0.06 1.18 (1.00-1.40) 0.05 
rs3853444 1.02 (0.88-1.17) 0.81 1.00 (0.86-1.16) 0.99 1.00 (0.86-1.16) 0.98 
rs17570669 0.60 (0.46-0.78) 2.0x10-4 0.67 (0.50-0.88) 4.7x10-3 0.66 (0.49-0.87) 3.6x10-3 
rs13130446 1.02 (0.90-1.16) 0.77 1.02 (0.89-1.17) 0.75 1.03 (0.90-1.18) 0.70 
rs10516564 0.86 (0.75-1.00) 0.05 0.86 (0.74-1.00) 0.05 0.86 (0.74-1.00) 0.05 
rs3866834 1.01 (0.88-1.16) 0.86 1.02 (0.89-1.18) 0.75 1.02 (0.89-1.18) 0.75 
rs4124163 0.55 (0.39-0.79) 1.0x10-3 0.56 (0.39-0.81) 2.3x10-3 0.56 (0.39-0.81) 2.3x10-3 
rs3853445 0.76 (0.65-0.90) 8.6x10-4 0.75 (0.64-0.89) 7.8x10-4 0.75 (0.64-0.89) 6.9x10-4 
rs6838901 0.88 (0.73-1.07) 0.20 0.91 (0.75-1.11) 0.36 0.91 (0.74-1.11) 0.33 
rs6838973 0.77 (0.68-0.88) 1.8x10-4 0.78 (0.68-0.90) 4.6x10-4 0.77 (0.67-0.89) 3.4x10-4 
 
Genomic position from NCBI build 36. 
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Supplemental Table 3. Pairwise linkage disequilibrium measures for rs2200733, rs17570669, 
rs6838973, and rs3853445 in the MGH, AFNET, and HapMap CEU samples.  
 
MGH  rs17570669 rs6838973 rs3853445 
 rs2200733 0.08 / 0.43 0.00 / 0.15 0.01 / 0.38 
 rs17570669  0.11 / 0.90 0.02 / 0.29 
 rs6838973   0.43 / 0.93 
 rs3853445    
     
AFNET  rs17570669 rs6838973 rs3853445 
 rs2200733 0.06 / 0.36 0.01 / 0.25 0.01 / 0.42 
 rs17570669  0.10 / 0.91 0.04 / 0.38 
 rs6838973   0.41 / 0.92 
 rs3853445    
     
HapMap CEU release 22 rs17570669 rs6838973 rs3853445 
 rs2200733 0.04 / 0.25 0.02 / 0.39 0.01 / 0.45 
 rs17570669  0.09 / 1.00 0.11 / 0.70 
 rs6838973   0.31 / 0.88 
 rs3853445    
 
Linkage disequilibrium values are represented as r2 / D’. 
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SUPPLEMENTAL FIGURES  
Supplemental Figure 1. Minor allele frequencies of SNPs tagging distinct atrial fibrillation susceptibility signals.   
 
The SNPs rs3853445 and rs6838973 tag the same AF susceptibility signal. 
*Prevalent sample 
†Incident sample 
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Supplemental Figure 2. Multimarker risk score for AF based on combined rs2200733, rs17570669, and rs3853445 genotypes, stratified by 
prevalent or incident AF status. 
 
The meta-analyzed relative risk of AF for each multimarker combination of rs2200733, rs17570669, and rs3853445 genotypes relative to the most common 
multimarker combination are shown. Only multimarker combinations with an average sample frequency of ≥ 0.2% are displayed, though the effects are adjusted 
for all potential combinations, as well as age, sex, and hypertension, or sex only (CCAF). Subjects with incomplete genotypes were not included. Risk alleles for 
AF were the T allele for rs2200733, the A allele for rs17570669, and the T allele for rs3853445. Samples with prevalent AF included MGH, AFNET, CCAF, CHS, 
and RS. Samples with incident AF included ARIC and RS. Relative risks correspond to odds ratios (prevalent AF) and hazard ratios (incident AF). 
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Supplemental Figure 3. Phylogenetic conservation at the chromosome 4q25 locus. 
 
Pairwise alignment of genomic sequences of 16 mammalian and vertebrate species to the human genome (hg18) are plotted 
between positions 111,728,759-112,034,944 at the chromosome 4q25 locus. Blue peaks correspond to regions of high sequence 
conservation, and are reflected in the multi-species alignment in green. Pale yellow lines indicate uncertainty in the genomic 
sequence. Three isoforms of PITX2 are displayed on the plot. SNPs tagging distinct AF susceptibility signals are indicated. Plot 
generated using the UCSC genome browser.8  
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